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Racial Disparities in Liver Transplantation 
for Hepatocellular Carcinoma Are Not  
Explained by Differences in Comorbidities, 
Liver Disease Severity, or Tumor Burden
Lara Dakhoul,1 Samer Gawrieh,1 Keaton R. Jones,1 Marwan Ghabril,1 Chelsey McShane,2 Eric Orman,1 Eduardo Vilar-Gomez ,1  
Naga Chalasani,1 and Lauren Nephew1
Black patients have higher mortality and are less likely to receive liver transplantation for hepatocellular carcinoma 
(HCC) than white patients. Reasons for these disparities have not been fully elucidated. Comorbid disease, liver dis-
ease severity, cirrhosis etiologies, and tumor characteristics were compared between black and white patients with 
HCC seen at the Indiana University Academic Medical Center from January 2000 to June 2014. Logistic regression 
was used to investigate the primary outcome, which was liver transplantation. Log-rank testing was used to compare 
survival between the two groups. Subgroup analysis explored reasons for failure to undergo liver transplantation in 
patients within Milan criteria. The cohort included 1,032 (86%) white and 164 (14%) black patients. Black and white 
patients had similar Model for End-Stage Liver Disease (MELD) and Child-Pugh scores (CPSs). There was a trend 
toward larger tumor size (5.3 cm versus 4.7 cm; P = 0.05) in black patients; however, Barcelona Clinic Liver Cancer 
(BCLC) staging and Milan criteria were similar. Black patients were less likely to undergo liver transplantation than 
white patients; this was a disparity that was not attenuated (odds ratio [OR], 0.43; 95% confidence interval [CI], 0.21-
0.90) on multivariable analysis. Substance abuse was more frequently cited as the reason black patients within Milan 
criteria failed to undergo transplantation compared to white patients. Survival was similar between the two groups. 
Conclusion: Racial differences in patient and tumor characteristics were small and did not explain the disparity in liver 
transplantation. Higher rates of substance abuse in black patients within Milan criteria who failed to undergo trans-
plantation suggest social factors contribute to this disparity in this cohort. (Hepatology Communications 2019;3:52-62).
Abbreviations: AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; BMI, body mass index; CAD, coronary artery disease; CDT, 
catheter-directed therapy; CI, confidence interval; CPS, Child-Pugh score; DM, diabetes mellitus; HCC, hepatocellular carcinoma; HCV, hepatitis 
C virus; MELD, Model for End-Stage Liver Disease; NAFLD, nonalcoholic fatty liver disease; OLT, orthotopic liver transplantation; OR, odds 
ratio; PVD, peripheral vascular disease; SBRT, stereotactic body radiation therapy; RFA, radio frequency ablation; TNM, tumor-node-metastasis.
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The incidence of hepatocellular carcinoma (HCC) has more than doubled in recent decades, making it one of the fastest-rising 
causes of cancer-related mortality in the United 
States.(1) Increases in both incidence and mor-
tality have disproportionately impacted black 
patients,(2) who have incidence rates twice that of 
their white counterparts.(3) In a recent Surveillance, 
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Epidemiology, and End Results (SEER) database 
study, the overall 5-year survival rate for patients 
with HCC was lower among black patients than 
any other racial group.(4)
Analyses exploring racial disparities in HCC 
outcomes have failed to fully explain this disparity 
on multivariable analysis.(5-7) Contributing factors 
that have been explored include late presentation, 
as black patients have been shown in some cohorts 
to be more likely to present with advanced tumor 
burden than white patients.(4) Other analyses have 
suggested disparities in curative therapies contribute 
to the racial disparity in HCC mortality.(8) Curative 
treatments for HCC include resection, ablation, 
and liver transplantation. However, only 20% of 
patients with HCC have sufficiently preserved liver 
function to undergo resection.(9) Therefore, liver 
transplantation is often the treatment of choice to 
cure both HCC and the underlying liver disease. 
Despite this, Wong et al.(8) found that from 2009 
to 2010, of those potentially eligible for liver trans-
plantation, only 11% of black patients underwent 
transplantation compared to 20% of white patients. 
Furthermore, even after adjusting for factors such as 
tumor stage, age, sex, treatment type, and income,(5-7) 
black patients remained significantly more likely 
than white patients to die from HCC.
More than 80% of patients with HCC have 
underlying liver cirrhosis(10); however, large cancer 
registry studies are limited in their ability to analyze 
liver disease etiology, severity, or comorbidities. The 
disparity seen in liver transplantation for HCC may 
be related to these patient-specific factors. Therefore, 
in an effort to better understand racial disparities 
in liver transplantation in patients with HCC, we 
sought to conduct a detailed study to compare these 
factors between black and white patients seen over a 
14.5-year period at a tertiary care transplant center.
Patients and Methods
All adult patients with HCC seen at the Indiana 
University Academic Medical Center from January 
2000 to June 2014 were identified using the Indiana 
State Cancer Registry. The study was reviewed and 
approved by the institutional review board at our 
institution and is compliant with ethical conduct of 
research. White and black patients with confirmed 
HCC by histologic and/or radiographic evidence were 
included in this study. Patients with fibrolamellar HCC 
or pure cholangiocarcinoma without combined HCC or 
belonging to other racial groups (n = 54) were excluded.
Clinical characteristics (including demographics 
and race), comorbidities, tumor characteristics, under-
lying liver disease etiologies, and treatment modalities 
received throughout the disease course were manually 
extracted from medical records. Chart documentation 
and laboratory data were used to judge the presence 
of medical comorbidities, including diabetes mellitus 
(DM), hypertension, hyperlipidemia, coronary artery 
disease (CAD), and peripheral vascular disease (PVD). 
Underlying liver disease etiologies were also collected, 
including hepatitis C virus (HCV), hepatitis B virus, 
alcoholic liver disease, nonalcoholic fatty liver disease 
(NAFLD), autoimmune liver diseases (autoimmune 
hepatitis, primary biliary cholangitis, and primary 
sclerosing cholangitis), and metabolic liver diseases 
(hemochromatosis and alpha-1 antitrypsin deficiency). 
We defined NAFLD as a diagnosis assigned by the 
patient’s hepatologist based on metabolic risk factors 
or, in the absence of this documentation, evidence 
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of hepatic steatosis, either by imaging or histology 
without an alternative liver disease etiology.(11) The 
remaining patients with cryptogenic cirrhosis without 
evidence of NAFLD were classified as other.
History of alcohol abuse was defined as “a history 
of more than 3 drinks a day, documentation of alco-
holism/alcohol abuse in a physician’s note, enrollment 
in a substance abuse treatment program, or history of 
alcoholic hepatitis.”(12)
Insurance information was obtained for each patient 
at the time of HCC diagnosis through the Regenstrief 
Institute.(13) The Regenstrief Institute manages the 
Indiana Network for Patient Care, a large regional 
health information exchange that contains information 
on 17 million unique patients over a 30-year period.(13) 
Types of insurance were grouped into four categories: 
Medicare, Medicaid, private, and self-pay.
The presence or absence of cirrhosis was assessed 
using criteria established by Mittal et al.(12) Patients 
were unclassified if there were insufficient data in the 
medical records. Child-Pugh score (CPS) and Model 
for End-Stage Liver Disease (MELD) score were cal-
culated only for patients with cirrhosis.
Tumor stage was defined using the tumor-node-me-
tastasis (TNM) stage; histologic grade, presence/
absence of Milan criteria,(14) and the original 
Barcelona Clinic Liver Cancer (BCLC) classification 
were captured at the time of diagnosis.(15) The size of 
the largest mass in centimeters was captured for each 
patient at the time of diagnosis.
The primary outcome was liver transplantation. 
The secondary outcome was combined liver trans-
plantation, resection, or ablation. Other noncura-
tive therapies, including catheter-directed therapies 
(CDTs), stereotactic body radiation therapy (SBRT), 
sorafenib treatment, and palliative care referral, were 
compared between the two groups.
Survival data were ascertained from the Indiana 
Cancer Registry and the Regenstrief Institute at 
Indiana.(13) The Regenstrief Institute links death 
data to patients in the Indiana Network for Patient 
Care, using a global match program. The overall sur-
vival period was computed using the date of HCC 
diagnosis and the date of death. For patients who 
were still alive or who died and their date of death 
was unknown, the date of last contact was used.
statistiCal analysis
Continuous variables are presented as mean ± SD 
or median with interquartile range and categorical 
variables as numbers and percentages. Chi-square 
testing was used for comparison between different 
groups for discrete variables and independent samples, 
and Mann-Whitney testing was used for continuous 
variables. A 2-tailed test with P < 0.05 was considered 
statistically significant. For categorical variables with 
cells that had expected counts less than 5, Fisher’s 
exact test was used. The trends of HCC over a 14.5-
year period were studied in three intervals (2000-2004, 
2005-2009, and 2010-June 2014). The linear-by-lin-
ear progression P value was used for the time-trend 
comparison between tested groups. Overall survival 
was calculated using the Kaplan-Meier method and 
log-rank test.
Logistic regression models were used to calculate 
odds ratio (OR) and 95% confidence interval (CI) 
for the primary outcome of liver transplantation and 
secondary combined curative outcome (liver trans-
plantation, resection, or ablation), by race (black 
versus white). To attempt to attenuate any disparity, 
we adjusted for demographics, liver disease sever-
ity, and other covariates in a stepwise approach. 
An interaction was explored with insurance status 
and race and was not significant. A similar analysis 
was performed with matched propensity scores (4:1 
match), using generalized linear mixed models to 
account for the matched groups, based on clinically 
relevant variables. Matched propensity scores were 
derived using the methods as outlined by Murphy 
and Fraeman.(16)
A subgroup analysis using the medical record and 
our liver transplant database to identify causes for 
failure to receive liver transplantation was then per-
formed on patients who were within Milan criteria 
(potential liver transplant candidates) but did not 
undergo transplantation. Black potential candidates 
were matched by age (±3 years) and sex with white 
potential candidates in a 1:1 ratio. Chi-square testing 
was then performed to compare the different causes 
of failure to receive a transplant between white and 
black patients.
All analyses were performed using Stata version 
14.0 (StataCorp LLC, College Station, TX) and 
SPSS version 24.0 (IBM Corp., Armonk, NY).
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taBle 1. CompaRison oF DemogRapHiCs anD CliniCal anD tumoR CHaRaCteRistiCs 
BetWeen BlaCk anD WHite patients WitH HCC.
Black Patients (n = 164) White Patients (n = 1,032) P Value
Demographics
Age (years), mean (SD) 59.7 (9.8) 62.0 (10.3) 0.005
Male sex (%) 70 74 0.33
BMI (kg/m2), mean (SD) 27.4 (6.3) 29.0 (6.2) 0.001
Comorbidities (%)
Hypertension 64 54 0.02
DM 37 38 0.78
Dyslipidemia 17 23 0.13
CAD 17 20 0.34
PVD 9 11 0.39
Alcohol abuse 59 42 <0.001
Liver disease characteristics
ALT (U/L), mean (SD) 69 (54) 73 (135) 0.03
AST (U/L), mean (SD) 124 (110) 111 (199) <0.001
Platelets (k/mm3), mean (SD) 172 (111) 142 (97) <0.001
Albumin (g/dL), mean (SD) 3.1 (0.6) 3.2 (0.7) 0.23
Total bilirubin (mg/dL), mean (SD) 2.4 (3.4) 2.3 (3.7) 0.95
MELD score, median (IQR) 11 (7) 11 (6) 0.16
Proportion Child-Pugh class C (%)* 21 20 0.79
Liver cirrhosis (%)† 92 88 0.22
Tumor severity
Tumor size (cm), mean (SD) 5.3 (3.8) 4.7 (3.8) 0.05
AFP (ng/mL) (%) 0.03
<20 38 49
20-200 32 23
>200 30 29
Tumors within Milan criteria (%) 42 48 0.19
BCLC stage (%) 0.60
A 25 24
B 7 11
C 47 44
D 21 22
Tumor grade (%) 0.09
Well 34 29
Moderate 39 54
Poor 27 17
Anaplastic 0 1
Type of insurance (%) 0.03
Medicare 38 46
Medicaid 16 9
Private 38 38
Self-pay 8 7
Treatment modalities received (%)
OLT 14 26 0.001
Palliative/hospice care 31 20 0.001
Surgical resection 10 16 0.06
CDT 38 39 0.74
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Results
There were 1,032 (86%) white and 164 (14%) 
black patients in the cohort (Table 1). Over the three 
time intervals of the study (2000-2004, 2005-2009, 
2010-2014), the numbers of HCC cases did not dif-
fer between black (14%, 14%, 13%, respectively) and 
white (86%, 86%, 87%) patients (P = 0.68).
DemogRapHiCs anD 
unDeRlying ComoRBiDities
Black patients with HCC were significantly younger 
(59.7 years versus 62.0 years; P = 0.005) with lower 
body mass index (BMI) (27.4 kg/m2 versus 29.0 kg/
m2; P = 0.001) than white patients. Black patients had 
more hypertension (64% versus 54%; P = 0.02) than 
white patients. Otherwise, there was no difference 
in the distribution of other comorbidities, including 
DM, dyslipidemia, CAD, and PVD, between the two 
groups (Table 1).
unDeRlying liVeR Disease 
etiology anD seVeRity
Overall, viral hepatitis and alcoholic liver disease 
were the most common etiologies of liver disease in 
the cohort. HCV and/or alcohol were underlying 
liver disease etiology in 77% of the black patients 
compared to 49% of the white patients (P < 0.001). 
NAFLD was very rare in black patients; only 1% 
of black patients had NAFLD compared to 19% of 
white patients (P < 0.001) (Fig. 1). There were no sig-
nificant differences in the occurrence of noncirrhotic 
Fig. 1. Distribution of liver disease etiologies among black and white patients. Abbreviation: HBV, hepatitis B virus.
Black Patients (n = 164) White Patients (n = 1,032) P Value
SBRT 15 12 0.26
RFA 2 3 0.61
Sorafenib 13 10 0.16
*CPS was only assessed for patients with cirrhosis.
†Unclassified cases excluded.
Abbreviations: AFP, alpha-fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; 
IQR, interquartile range; OLT, orthotopic liver transplantation; RFA, radio frequency ablation.
taBle 1. CONTINUED 
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HCC between black and white patients (8% versus 
12%; P = 0.22) (Table 1).
Platelet count was significantly higher in black 
patients than white patients (172 k/mm3 versus 
142 k/mm3; P < 0.001). Otherwise, black and white 
patients had similar MELD scores (median, 11 for 
both groups; P = 0.16) and CPS (21% versus 20% 
Child-Pugh class C patients; P = 0.79) (Table 1).
tumoR CHaRaCteRistiCs
There was a trend toward larger tumor size in 
black patients compared to white patients (5.3 cm 
versus 4.7 cm; P = 0.05); black patients also had 
higher alpha-fetoprotein (AFP) levels (62% versus 
52% had AFP >20 ng/mL; P = 0.02) than white 
patients. Although black patients presented with 
more advanced TNM stage, there was no differ-
ence in the distribution of BCLC stages and histo-
logic tumor differentiation between the groups. The 
numbers of patients within Milan criteria were sim-
ilar between black (42%) and white (48%) patients 
(P = 0.19) (Table 1).
HistoRy oF alCoHol aBuse 
anD insuRanCe status
Of the 1,145 patients with known insurance sta-
tus, 45% had Medicare, 38% had private insurance, 
10% had Medicaid, and 8% were self-pay. White 
patients were more likely to have Medicare (46% 
versus 38%) than black patients, but the opposite 
was true for Medicaid (16% black versus 9% white; 
P = 0.03). Forty-four percent of our study population 
had a history of alcohol abuse; however, alcohol abuse 
history was more prevalent in black patients than 
white patients (59% versus 42%; P < 0.001). Medicaid 
patients (63%) were significantly more likely than 
Medicare (35%), privately insured (48%), or self-pay 
(17%) patients to have a history of alcohol abuse (P 
< 0.001).
tReatments anD outComes
Black patients were significantly less likely to 
undergo transplantation compared to white patients 
(14% versus 26%; P = 0.001) and more likely to 
receive palliative and/or hospice care (31% versus 
20%; P = 0.001). The proportion of patients who 
underwent resection or received CDT, SBRT, radio 
frequency ablation (RFA), or sorafenib at any point 
throughout their disease course was similar in both 
groups (Table 1).
On univariable analysis, black patients were less 
likely to undergo transplantation than white patients 
(OR, 0.46; 95% CI, 0.29-0.73) (Table 2). The dispar-
ity was not attenuated when the following variables 
were added to the model in a stepwise approach: age, 
BMI, underlying comorbidities (OR, 0.35; 95% CI, 
0.21-0.60), liver disease etiology and severity (OR, 
0.42; 95% CI, 0.23-0.75), tumor characteristics (OR, 
0.43; 95% CI, 0.22-0.85), insurance status, and history 
of alcohol use (OR, 0.43; 95% CI, 0.21-0.90). This 
analysis was repeated in a cohort limited to diagnosis 
from 2002 to 2014 (after introduction of the MELD 
score), and the disparity remained on univariable and 
multivariable analysis. On univariable analysis, black 
patients were also less likely to achieve the secondary 
combined curative outcome of liver transplantation, 
resection, or ablation (OR, 0.44; 95% CI, 0.30-0.64). 
This disparity was also not attenuated on multivari-
able analysis (OR, 0.43; 95% CI, 0.23-0.83) (Table 2). 
Results of a propensity score match were similar to 
the standard unadjusted and adjusted logistic regres-
sion models, with similar P values and point estimates 
for the OR and with only a slight increase in CI width 
(OR, 0.49; 95% CI, 0.27-0.89).
To further explore this disparity, a subgroup anal-
ysis was performed on patients with HCC within 
Milan criteria who did not undergo liver transplanta-
tion (potential liver transplant candidates). Sixteen out 
taBle 2. multiVaRiaBle analysis: 
CompaRison oF pRimaRy outCome 
tRansplant anD seConDaRy outCome 
tRansplant, ReseCtion, oR aBlation 
BetWeen BlaCk anD WHite patients
Univariable 
Analysis
Multivariable 
Analysis†
OR (95% CI) OR (95% CI)
Liver transplantation* 0.46 (0.29-0.73) 0.43 (0.21-0.90)
Liver transplantation, 
resection, or ablation*
0.44 (0.30-0.64) 0.43 (0.23-0.83)
*White race used as reference.
†Multivariable analysis included age, BMI, comorbidities (hyper-
tension, CAD, and PVD), liver disease severity (CPS and liver cir-
rhosis), liver disease etiologies, tumor characteristics (tumor size, 
Milan status, and BCLC), insurance, and history of alcohol abuse.
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of 68 (24%) black patients and 208 out of 474 (44%) 
white patients within Milan criteria underwent trans-
plantation (P = 0.001) (Fig. 2). Alcohol or drug abuse 
was the most common reason for not undergoing liver 
transplantation in both races (25 out of 88 patients; 
28%), followed by medical comorbidities and older 
age (19%) (Table 3). Nearly 15% of patients within 
Milan criteria were never referred for liver transplan-
tation, and 10% after referral reported they were not 
interested. Black potential liver transplant candidates 
were significantly more likely than white potential 
liver transplant candidates to be declined transplan-
tation because of alcohol and drug abuse (39% versus 
18%; P = 0.03). Although insurance status did not 
explain the disparity seen in liver transplantation on 
multivariable analysis, 42% of white potential liver 
transplant candidates with Medicaid underwent liver 
transplantation compared to 17% of black potential 
liver transplant candidates with Medicaid.
The 1-year (54% versus 56%; P = 0.41), 3-year 
(27% versus 32%; P = 0.20), and 5-year (14% versus 
20%; P = 0.07) survival rates were similar in black 
and white patients, respectively. When explored by 
transplant status, the 1-year, 3-year, and 5-year sur-
vival rates between the two groups also did not differ 
(Table 4; Fig. 3).
Fig. 2. Flow diagram comparing the proportion of patients within Milan criteria who did or did not receive surgical resection/liver 
transplantation in both races.
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Discussion
Black patients are disproportionately impacted by 
increasing incidence of and mortality from HCC. 
Reasons for this disparity are not clear, and a long-
term in-depth review of a large cohort of black patients 
has been lacking in the literature. In this study, we 
sought to compare demographics, underlying comor-
bidities, liver disease etiologies, tumor characteristics, 
treatment modalities, and survival between white 
and black patients with HCC seen at a tertiary care 
transplant center, as these factors may explain the dis-
parities that continue to be reported. Ultimately, our 
study found that black patients were significantly less 
likely to undergo transplantation than white patients 
and more likely to receive palliative care or hospice. 
They also had more hypertension and viral hepatitis, 
trended toward larger tumors, and were more likely to 
have Medicaid. These factors, however, did not explain 
the disparity in liver transplantation. Interestingly, 
despite being less likely to undergo transplantation, 
black patients seen at a tertiary care center had similar 
1-year, 3-year, and 5-year survival to white patients.
In our study, black patients with HCC were 54% 
less likely to undergo transplantation than white 
patients. This finding has been consistently reported 
in the last decade.(6,17,18) In a recent SEER analysis 
of patients within Milan criteria under the age of 65 
years, 20% of white patients underwent liver trans-
plantation compared to 11% of black patients.(8)
Many explanations have been proposed for these 
disparities, including concerns that black patients 
present with more advanced diseases, more comorbid 
illnesses, or more severe liver disease. In our study, 
black patients were more likely to have hypertension 
and just as likely to have CAD or PVD, diseases that 
often preclude liver transplantation. They also trended 
toward larger tumors and more advanced TNM stag-
ing. However, the staging used to determine liver 
transplantation eligibility (BCLC and Milan crite-
ria) was similar between the white and black patients. 
An analysis of 63 black patients seen at Columbia 
University found they had more advanced HCC, 
higher CPS, more comorbid disease,(17) and poorer 
1-year, 3-year, and 5-year survival than white patients. 
In our study, 42% of black patients were within 
Milan criteria compared to only 23% in the cohort 
at Columbia.(17) These data suggest that patients seen 
at our tertiary care center may be healthier and pre-
sent earlier than black patients seen at other trans-
plant institutions. This may also reflect a referral bias, 
with only healthier black patients being referred to 
our center.
taBle 3. suBgRoup analysis: main Reasons 
FoR not ReCeiVing liVeR tRansplantation 
in patients WitH tumoRs WitHin milan 
CRiteRia in BotH RaCe gRoups
Cause
Black 
Patients 
(n = 44)
White 
Patients 
(n = 44) P Value
Ongoing alcohol/drug abuse 
(n = 25) (%)
39 18 0.03
Comorbidities/malignancy/older 
age (n = 17) (%)
21 18 NS
Never referred (n = 13) (%) 16 14 NS
Not interested in OLT (n = 9) (%) 5 16 NS
Insurance/financial problems  
(n = 6) (%)
7 7 NS
Lost to follow-up (n = 6) (%) 5 9 NS
Too sick/died before transplanta-
tion (n = 5) (%)
0 11 -
Unknown/insufficient information 
(n = 5) (%)
7 5 NS
Noncompliance (n = 1) (%) 2 0 -
Lack of social support (n = 1) (%) 0 2 -
Abbreviation: NS, not significant.
taBle 4. CompaRison oF suRViVal  
Rates BetWeen BlaCk anD WHite  
patients WitH HCC
Black 
Patients 
(n = 164)
White Patients 
(n = 1,032) P Value
Overall survival rates 
(%)
1 year 54 56 0.41
3 years 27 32 0.20
5 years 14 20 0.07
Survival rates of patients 
who received OLT (%)
1 year 78 81 0.61
3 years 68 61 0.48
5 years 43 44 0.97
Survival rates of patients 
who did not receive 
OLT (%)
1 year 48 39 0.21
3 years 16 11 0.18
5 years 5 4 0.19
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Conventional explanations for racial disparities 
in liver transplantation did not explain the disparity 
in our cohort. Although black patients had slightly 
larger tumor size and there was a complex relation-
ship between race, insurance status, and receipt of 
liver transplantation, these factors did not attenuate 
the disparity. Furthermore, when comorbidities, liver 
disease etiology, and tumor severity were added to 
multivariable models, the differences in liver trans-
plantation were not attenuated. This prompted a sub-
group analysis that revealed a number of social factors 
prohibited potential candidates from undergoing liver 
transplantation. Thirty-nine percent of black patients 
compared to 18% of white patients within Milan cri-
teria had ongoing alcohol or drug abuse. Throughout 
the study period, our institution’s alcohol policy 
required 6 months of sobriety as well as completion 
of an alcohol treatment program for patients sober 
less than 2 years. Lack of referral, lack of insurance, 
financial issues, and lack of interest in liver transplan-
tation were other factors that prohibited potential 
candidates from undergoing transplantation. These 
social factors appear to be pivotal in these potential 
candidates’ failure to undergo liver transplantation. 
The social determinants of health are the structural 
determinants and conditions in which people are 
born, grow, live, work, and age.(19) They include fac-
tors such as socioeconomic status, the physical envi-
ronment, employment, and social support networks 
as well as access to health care.(19) The distributions 
of economic and social conditions among the popu-
lation are known to influence individual and group 
Fig. 3. Kaplan-Meier survival curves. (A) Overall survival. (B) Survival in patients who underwent liver transplantation. (C) Survival 
in patients who did not undergo liver transplantation.
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differences in health status.(20) Deficiencies in these 
areas may disproportionately affect black patients.(20)
Although our study identified disparities in liver 
transplantation, survival in black and white patients 
without liver transplantation was similar. There were 
few differences in comorbidity and disease severity in 
our cohort to explain black patients’ similar survival 
to white patients despite the disparity in liver trans-
plantation. Black patients in our cohort, however, were 
more likely to receive palliative care. Palliative care has 
been shown to lead to less aggressive care at the end 
of life but longer survival in non-small cell lung can-
cer.(21) This is a provocative hypothesis for the similar 
survival between black patients and white patients in 
our cohort that will require further study.
Our study strength is that it contains comorbidities, 
underlying liver disease severity, and tumor character-
istics on the largest cohort of black and white patients 
with HCC to date. We also have a transplant database 
that allows us to perform a detailed subgroup analysis 
on potential liver transplant candidates. This analysis 
revealed interesting hypothesis-generating findings 
about reasons for failure to undergo transplantation. 
Our study is limited because it contains data from one 
academic medical center. However, our center is the 
only transplant center in the state and is located in the 
heart of metropolitan Indianapolis where more than 
75% of HCC occurs in black patients. Nevertheless, 
after comparison to the state cancer registry, we esti-
mated that we captured only approximately 25% of 
black patients with HCC. This referral practice high-
lights potential disparities in HCC care for black 
patients and warrants further study. It is likely that 
black patients who are referred and seen at our ter-
tiary care transplant center compose a select subgroup 
within a more widely disadvantaged population of 
black patients with cirrhosis with HCC. Even in this 
select group, significant disparities in liver transplan-
tation are still seen. Although treatments for HCC 
vary by center and our institutional practice for treat-
ment of HCC trends toward resection and SBRT and 
less toward ablation, there were no differences seen in 
these therapies by race. Furthermore, this should not 
impact the disparity seen in liver transplantation.
Black and white patients had different etiolo-
gies of their underlying liver disease, but their liver 
disease severity was comparable. Differences in 
comorbidities and tumor severity were minor in this 
cohort. Black patients were significantly less likely to 
undergo liver transplantation, a disparity that could 
not be accounted for by comorbid illness, liver disease 
severity, tumor characteristics, or insurance status. 
Nevertheless, mortality was similar between black 
and white patients seen at a tertiary care transplant 
center. Subgroup analysis suggests that racial dispar-
ities in liver transplantation in a cohort referred to a 
tertiary care transplant center are largely driven by 
social factors that warrant further study.
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